CN104324330A - 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 - Google Patents
一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN104324330A CN104324330A CN201410669028.4A CN201410669028A CN104324330A CN 104324330 A CN104324330 A CN 104324330A CN 201410669028 A CN201410669028 A CN 201410669028A CN 104324330 A CN104324330 A CN 104324330A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- chinese medicine
- medicine composition
- extracting solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000008280 blood Substances 0.000 title abstract description 126
- 210000004369 blood Anatomy 0.000 title abstract description 123
- 238000009825 accumulation Methods 0.000 title abstract description 7
- 241000255626 Tabanus <genus> Species 0.000 claims abstract description 27
- 239000004863 Frankincense Substances 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 210000000582 semen Anatomy 0.000 claims description 47
- 239000000243 solution Substances 0.000 claims description 44
- 239000000284 extract Substances 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 27
- 239000009636 Huang Qi Substances 0.000 claims description 24
- 241000628997 Flos Species 0.000 claims description 22
- 241000237636 Pheretima Species 0.000 claims description 22
- 241000717739 Boswellia sacra Species 0.000 claims description 21
- 241001489978 Eupolyphaga Species 0.000 claims description 21
- 241000283956 Manis Species 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- -1 sublimed preparation Substances 0.000 claims description 4
- 241000792859 Enema Species 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 239000007920 enema Substances 0.000 claims description 3
- 229940095399 enema Drugs 0.000 claims description 3
- 239000002662 enteric coated tablet Substances 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007940 sugar coated tablet Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 80
- 230000017531 blood circulation Effects 0.000 abstract description 40
- 210000000952 spleen Anatomy 0.000 abstract description 32
- 210000003734 kidney Anatomy 0.000 abstract description 30
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract description 2
- 241000759833 Cornus officinalis Species 0.000 abstract description 2
- 241000361919 Metaphire sieboldi Species 0.000 abstract description 2
- 240000005373 Panax quinquefolius Species 0.000 abstract description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 2
- 235000000664 Rosa chinensis Nutrition 0.000 abstract description 2
- 229910052802 copper Inorganic materials 0.000 abstract description 2
- 239000010949 copper Substances 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000218993 Begonia Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 241000282461 Canis lupus Species 0.000 abstract 1
- 241000131329 Carabidae Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000122904 Mucuna Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 240000008254 Rosa chinensis Species 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 241000301400 Trogopterus Species 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 60
- 230000036407 pain Effects 0.000 description 54
- 230000001737 promoting effect Effects 0.000 description 45
- 210000004185 liver Anatomy 0.000 description 30
- 210000002216 heart Anatomy 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 208000029312 Muscular tumor Diseases 0.000 description 19
- 201000000736 Amenorrhea Diseases 0.000 description 18
- 206010001928 Amenorrhoea Diseases 0.000 description 18
- 210000001015 abdomen Anatomy 0.000 description 18
- 231100000540 amenorrhea Toxicity 0.000 description 18
- 235000009508 confectionery Nutrition 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 18
- 208000027744 congestion Diseases 0.000 description 17
- 206010007247 Carbuncle Diseases 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 206010011224 Cough Diseases 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 210000004291 uterus Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 208000006820 Arthralgia Diseases 0.000 description 12
- 208000005171 Dysmenorrhea Diseases 0.000 description 12
- 206010013935 Dysmenorrhoea Diseases 0.000 description 12
- 230000004087 circulation Effects 0.000 description 12
- 208000004998 Abdominal Pain Diseases 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 11
- 208000007106 menorrhagia Diseases 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 230000003014 reinforcing effect Effects 0.000 description 11
- 206010000077 Abdominal mass Diseases 0.000 description 10
- 206010019233 Headaches Diseases 0.000 description 10
- 208000004880 Polyuria Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 230000035619 diuresis Effects 0.000 description 10
- 231100000869 headache Toxicity 0.000 description 10
- 241000411851 herbal medicine Species 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 206010000087 Abdominal pain upper Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002398 materia medica Substances 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000008736 traumatic injury Effects 0.000 description 9
- 208000019255 Menstrual disease Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 208000033809 Suppuration Diseases 0.000 description 7
- 230000001788 irregular Effects 0.000 description 7
- 201000007227 lymph node tuberculosis Diseases 0.000 description 7
- 230000002175 menstrual effect Effects 0.000 description 7
- 230000005906 menstruation Effects 0.000 description 7
- 230000027758 ovulation cycle Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 6
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 206010040943 Skin Ulcer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 208000001780 epistaxis Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 231100000019 skin ulcer Toxicity 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001166 anti-perspirative effect Effects 0.000 description 4
- 239000003213 antiperspirant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000004396 mastitis Diseases 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002048 spasmolytic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000004576 Placental Lactogen Human genes 0.000 description 3
- 108010003044 Placental Lactogen Proteins 0.000 description 3
- 239000000381 Placental Lactogen Substances 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000013219 diaphoresis Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000001617 migratory effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010062104 Renal mass Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002158 anti-implantation Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100288498 Mus musculus Large1 gene Proteins 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010034240 Pelvic congestion Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004190 broad ligament Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000044 progesterone antagonist Substances 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 210000004061 pubic symphysis Anatomy 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000001139 rectus abdominis Anatomy 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000121 skin sensitizing Toxicity 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000010681 turmeric oil Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗淤血蓄结型子宫肌瘤功能的中药组合物及其制备方法,中药组合物包括以下原料药材:柴胡、桃仁、穿山甲、桂枝、甘草、当归、生地、牛膝、地龙、川芎、五灵脂、蒲黄、天仙藤、乳香、刺蒺藜、王不留行、月季花、虻虫、黄芪、山药、山茱萸、西洋参、土鳖虫、蜂房、莪术、丹皮、羊红膻、瓦楞子、自然铜、秋海棠根、牛马藤。本发明提供的中药组合物能够活血化瘀,软坚散结,治疗淤血蓄结型子宫肌瘤,兼以补脾益肾,扶助正气,治疗子宫肌瘤,疗程短、效果较好、残留量低,制作工艺简便,毒副作用小且给药方便。
Description
技术领域
本发明涉及中药技术领域,特别涉及一种治疗子宫肌瘤的中药组合物及其制备方法。
背景技术
子宫肌瘤是女性生殖器官中最常见的一种良性肿瘤,也是人体中最常见的肿瘤之一,又称为纤维肌瘤、子宫纤维瘤。由于子宫肌瘤主要是由子宫平滑肌细胞增生而成,其中有少量纤维结缔组织作为一种支持组织而存在,故称为子宫平滑肌瘤较为确切。简称子宫肌瘤。多见于30—50岁妇女,以40—50岁最多见,20岁以下少见,35岁以上约20%妇女有子宫肌瘤。一般好发于生殖年龄妇女,绝经后肌瘤停止生长,甚至萎缩、消失。
有关子宫肌瘤的病因迄今仍不十分清楚,病因可能涉及到正常肌层的细胞突变、性激素及局部生长因子间的较为复杂的相互作用。根据大量临床观察和实验结果表明子宫肌瘤是一种激素依赖性肿瘤。雌激素是促使肌瘤生长的主要因素,还有学者认为生长激素(GH)与肌瘤生长亦有关,GH能协同雌激素促进有丝分裂而促进肌瘤生长,并推测人胎盘催乳素(HPL)也能协同雌激素促有丝分裂作用,认为妊娠期子宫肌瘤生长加速除与妊娠期高激素环境有关外,可能HPL也参加了作用。此外卵巢功能、激素代谢均受高级神经中枢的控制调节,故神经中枢活动对肌瘤的发病也可能起重要作用。因子宫肌瘤多见于育龄、丧偶及性生活不协调的妇女。长期性生活失调而引起盆腔慢性充血也可能是诱发子宫肌瘤的原因之一。总之,子宫肌瘤的发生发展可能是多因素共同作用的结果。多数患者无症状,仅在盆腔检查或超声检查时偶被发现。如有症状则与肌瘤生长部位、速度、有无变性及有无并发症关系密切,而与肌瘤大小、数目多少关系相对较小。患有多个浆膜下肌瘤者未必有症状,而一个较小的黏膜下肌瘤常可引起不规则阴道流血或月经过多。
临床上常见的症状有:(1)子宫出血(2)腹部包块及压迫症状(3)疼痛(4)白带增多(5)不孕与流产(6)贫血(7)其他。
临床上常见体征有:(1)腹部检查 子宫增大超过3个月妊娠大小或较大宫底部浆膜下肌瘤,可在耻骨联合上方或下腹部正中扪及包块,实性,无压痛,若为多发性子宫肌瘤则肿块之外形呈不规则状。(2)盆腔检查 妇科双合诊、三合诊检查,子宫呈不同程度增大,欠规则,子宫表面有不规则突起,呈实性,若有变性则质地较软。
现代医学认为,子宫肌瘤的治法有:1、药物治疗:(1)促性腺激素 释放激素激动剂(GnRH-a)目前临床上常用的GnRH-a有亮丙瑞林(抑那通)、戈舍瑞林(诺雷德)、曲普瑞林(达必佳)等。GnRH-a不宜长期持续使用,仅用于手术前的预处理,一般用3~6个月,以免引起低雌激素引起的严重更年期症状;也可同时补充小剂量雌激素对抗这种副作用。(2)米非司酮 是一种孕激素拮抗剂,近年来临床上试用以治疗子宫肌瘤,可使肌瘤体积缩小,但停药后肌瘤多再长大。(3)达那唑 用于术前用药或治疗不宜手术的子宫肌瘤。停药后子宫肌瘤可长大。服用达那唑可造成肝功能损害,此外还可有雄激素引起的副作用(体重增加、痤疮、声音低钝等)。2、.手术治疗:子宫肌瘤的手术治疗包括肌瘤切除术及子宫切除术,可经腹部亦可经阴道进行,也可行内镜手术(宫腔镜或腹腔镜)。术式及手术途径的选择取决于患者年龄、有否生育要求、肌瘤大小及生长部位、医疗技术条件等因素。但其疗效不理想,并且毒副作用较大,价格昂贵,广大患者不容易接受现代医学治疗方案。中医药治疗疗效显著且制作工艺简便,毒副作用小且给药方便,能直达病灶,疗程较短,治愈后不易复发,药剂易于制造,成本低廉。
中医认为子宫肌瘤发病之初,邪尚不盛而正亦未衰,其临床表现比较轻,体征也不甚明显。随病情发展,可进入本病的典型阶段,出现症状和体征的改变,因宫腔、宫内膜面积增大,宫缩不良或子宫内膜增生过长致使月经周期缩短、经量增多、经期延长、不规则阴道流血等,黏膜下肌瘤一旦坏死、感染,则有持续性或不规则阴道流血或脓血性排液等,此期属邪盛而正尚未衰时期。发展至中后期,则可出现乏力、贫血等正气渐衰之候。当然发病的症状也会因瘤因人而异,需检查明确后再做诊断。
主要分为以下3种症型:(1)气滞血瘀型:主要表现是月经先后无定期,经量比较正常,有人有略多的表现,且经期延长,淋漓难以干净,腹胀坠痛,乳房胀痛,苔薄白或有紫气,脉弦涩。经检查发现,患者子宫略大,质中或偏硬,B 超显示瘤体较小。 (2)瘀血蓄结型:主要的表现是月经量多如涌、色紫有血块、下腹有刺痛感不能按住,有的人月经来的时候持续时间长,很难干净,舌紫黯有瘀斑,脉沉涩。经检查发现,子宫均匀或不对称增大,质感较硬,能触及单个或多个突起,在B 超下显示瘤体较大或数目较多。 (3)脾虚血瘀型:主要的表现是月经量多如注,月经的颜色呈淡紫,小腹有坠胀疼痛,会有头昏乏力,食欲不振的感觉,脸色少华,有人还伴有腹泻症状,舌体胖大有紫气,苔薄白或腻,脉细涩。 (4)肾虚血瘀型:主要表现为月经量多且淋漓难净,色紫黯有块,小腹隐痛,腰骶酸楚、头晕耳鸣,舌淡紫有齿痕或瘀点,脉沉细涩,容易造成不孕或堕胎,滑胎的情况,要给予重视。
发明内容
本发明所要解决的技术问题在于,提供了一种具有活血化瘀,软坚散结,兼以补脾益肾,扶助正气的功效,主治淤血蓄结型子宫肌瘤;配方简单、制作工艺简便,毒副作用小且给药方便,药剂易于制造,成本低廉的新药。本发明为中药组合物,但精选气味平和的中药,使中药组合物的气味并不浓烈。
为了实现上述发明目的,本发明提供了一种治疗淤血蓄结型子宫肌瘤的中药组合物,其中,所述中药组合物包括以下原料药材:柴胡、桃仁、穿山甲、桂枝、甘草、当归、生地、牛膝、地龙、川芎、五灵脂、蒲黄、天仙藤、乳香、刺蒺藜、王不留行、月季花、虻虫、黄芪、山药、山茱萸、西洋参、土鳖虫、蜂房、莪术、丹皮、羊红膻、瓦楞子、自然铜、秋海棠根、牛马藤。
其中,所述原料药材的重量份数比为:柴胡10-26重量份、桃仁12-20重量份、穿山甲13-25重量份、桂枝10-20重量份、甘草15-25重量份、当归10-24重量份、生地12-28重量份、牛膝10-20重量份、地龙12-24重量份、川芎10-20重量份、五灵脂12-23重量份、蒲黄10-20重量份、天仙藤15-22重量份、乳香10-20重量份、刺蒺藜12-23重量份、王不留行10-20重量份、月季花12-24重量份、虻虫3-8重量份、黄芪10-20重量份、山药5-10重量份、山茱萸10-20重量份、西洋参12-25重量份、土鳖虫3-8重量份、蜂房10-20重量份、莪术3-7重量份、丹皮10-20重量份、羊红膻10-18重量份、瓦楞子12-24重量份、自然铜10-20重量份、秋海棠根10-18重量份、牛马藤12-25重量份。
其中,所述原料药材的重量份数比为:柴胡20-26重量份、桃仁15-20重量份、穿山甲20-25重量份、桂枝16-20重量份、甘草20-25重量份、当归20-24重量份、生地20-28重量份、牛膝15-20重量份、地龙20-24重量份、川芎16-20重量份、五灵脂20-23重量份、蒲黄16-20重量份、天仙藤18-22重量份、乳香16-20重量份、刺蒺藜18-23重量份、王不留行16-20重量份、月季花20-24重量份、虻虫6-8重量份、黄芪16-20重量份、山药8-10重量份、山茱萸16-20重量份、西洋参20-25重量份、土鳖虫6-8重量份、蜂房16-20重量份、莪术5-7重量份、丹皮15-20重量份、羊红膻15-18重量份、瓦楞子20-24重量份、自然铜16-20重量份、秋海棠根15-18重量份、牛马藤20-25重量份。
其中,所述原料药材的重量份数比为:柴胡10重量份、桃仁12重量份、穿山甲13重量份、桂枝10重量份、甘草15重量份、当归10重量份、生地12重量份、牛膝10重量份、地龙12重量份、川芎10重量份、五灵脂12重量份、蒲黄10重量份、天仙藤15重量份、乳香10重量份、刺蒺藜12重量份、王不留行10重量份、月季花12重量份、虻虫3重量份、黄芪10重量份、山药5重量份、山茱萸10重量份、西洋参12重量份、土鳖虫3重量份、蜂房10重量份、莪术3重量份、丹皮10重量份、羊红膻10重量份、瓦楞子12重量份、自然铜10重量份、秋海棠根10重量份、牛马藤12重量份。
其中,所述原料药材的重量份数比为:柴胡26重量份、桃仁20重量份、穿山甲25重量份、桂枝20重量份、甘草25重量份、当归24重量份、生地28重量份、牛膝20重量份、地龙24重量份、川芎20重量份、五灵脂23重量份、蒲黄20重量份、天仙藤22重量份、乳香20重量份、刺蒺藜23重量份、王不留行20重量份、月季花24重量份、虻虫8重量份、黄芪20重量份、山药10重量份、山茱萸20重量份、西洋参25重量份、土鳖虫8重量份、蜂房20重量份、莪术7重量份、丹皮20重量份、羊红膻18重量份、瓦楞子24重量份、自然铜20重量份、秋海棠根18重量份、牛马藤25重量份。
为了解决上述技术问题,本发明还提供了一种治疗淤血蓄结型子宫肌瘤的中药组合物的制备方法,其中,所述中药组合物的剂型为胶囊剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~5倍的醇浓度为80~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得350目~400目的超微细粉;
第三步,在第二步获得的超微细粉中依次加入滑石粉、硬脂酸镁,进行混匀处理,即得胶囊内容物;所述超微细粉、硬脂酸镁和滑石粉的重量比为100∶0.02~0.1:0.01~0.1,将所述胶囊内容物装入胶囊壳体中,即得胶囊剂。
其中,所述中药组合物的剂型为片剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得250目~400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.01~0.3倍的微晶纤维素、0.05~0.1倍乳糖、0.02~0.2倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.001~0.01倍硬脂酸镁,整粒,压片,制成。
所述中药组合物的剂型为:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、蜜丸剂、散剂、丹剂、溶液剂、注射剂、栓剂、硬膏剂、糖浆剂、散剂、灌肠剂和贴剂。
本发明的有益效果是:本发明的中药药物,利用我国传统的中医理论,以活血化瘀,软坚散结,兼以补脾益肾,扶助正气为主,治疗瘀血蓄结型子宫肌瘤。本技术具有给药方便,直达病患部位,采用不同药性的中药材,进行了科学配伍,靶向性强,能达到理想的治疗效果,药剂易于制造,成本低廉等优点;本发明在传统医学的基础上结合多年临床经验,采用现代加工方法精心研制而成。本发明对组份药品的各有效成分科学配伍,是一种见效快、无任何毒副作用、效果持续久的中药组合物,且内外结合,标本兼治,能较大程度上解决患者的痛苦。
具体实施方式
中医称子宫肌瘤为“石瘕”,病因为肝、脾、肾三脏功能失调,气滞血瘀,或阴寒凝滞,或热耗伤津等有关。因肝胆郁滞而化火,湿热下注则为带下;因脾失健运,湿从内生则可见痰凝气滞留于宫中;肾精亏损,精血暗耗,瘀血恶血留聚宫中。故《素问·骨空论》日:“任脉为病,女子带下瘕聚”,使用中药宫瘤化消方针对瘕块治疗,采取活血化瘀、理气止痛、化痞消瘕之法。同时立足于整体,通过调理脏腑,促进整体机能改善,从而提高疗效,达扶正固本之目的。子宫肌瘤的早期,绝大多数无症状,往往在妇女普查或B超检查时被发现。倘若肌瘤的生长影响子宫腔的形态或子宫内膜面积的改变,或为黏膜下肌瘤,或长在特殊部位(如子宫颈、阔韧带内),或肌瘤较大、增长速度过快,则可引起一系列的临床症状,中医治疗子宫肌瘤一般是从活血化瘀,软坚散结,兼以补脾益肾,扶助正气着手,通过全面调理女性各脏器功能,调整内分泌,改善微循环,清除体内淤积,从而达到消除子宫肌瘤的目的。
为解决上述技术问题,本发明提供了一种治疗淤血蓄结型子宫肌瘤的中药组合物,其中,所述中药组合物包括以下原料药材:柴胡、桃仁、穿山甲、桂枝、甘草、当归、生地、牛膝、地龙、川芎、五灵脂、蒲黄、天仙藤、乳香、刺蒺藜、王不留行、月季花、虻虫、黄芪、山药、山茱萸、西洋参、土鳖虫、蜂房、莪术、丹皮、羊红膻、瓦楞子、自然铜、秋海棠根、牛马藤。
其中,;桃仁、穿山甲、桂枝、甘草、当归、生地、牛膝、地龙、川芎、五灵脂、蒲黄、天仙藤、乳香调气活血;刺蒺藜下气行血;王不留行、月季花活血;土鳖虫逐瘀;虻虫、丹皮、羊红膻、瓦楞子、自然铜、秋海棠根、牛马藤活血化瘀;另外,山药、山茱萸益肾,莪术、蜂房、柴胡、黄芪、西洋参补气正气辅助治疗。各组分,君臣辅佐,相辅相成,为中药组合物治疗提供各组分的功效。
现将各味中药药理性质分述如下:
柴胡:性微寒、味苦、辛、归肝经、胆经,具疏肝利胆、疏气解郁、散火之功效。功能:透表泄热,疏肝解郁,升举阳气。主治:治感冒发热、寒热虚劳发热。小儿痘疹余热,面黄肌瘦腹部膨大,疟疾,肝郁气滞,胸肋胀痛,脱肛,子宫脱落,月经不调。
桃仁:味苦甘而性平,能入心、肝、大肠,活血祛瘀作用甚广,可用治瘀血阻滞各种敝症。 用于症瘕结块,肺痈肠痈,跌仆伤痛,经闭痛经,产后瘀痛等症。本品水煎醇沉液可使离体兔耳静脉血管流量增加,有舒张血管作用。本品在的蛋白成分中的两个均一蛋白成分,静脉注射给药,对二甲苯所致小鼠耳急性炎症反应,均有显著抑制作用。桃仁水提物能抑制小鼠血清中的皮肤过敏抗体及鼷鼠脾溶血性细胞的产生,其乙醇提取物口服能抑制小鼠含有皮肤过敏性抗体的抗血清引起的PCA反应(被动皮肤过敏反应)的色素渗出量。苦否仁甙,有镇咳作用。桃仁中的脂肪油(扁桃油)有驱虫作用,对蛲虫的驱虫效果为80.8%,对蛔虫效果为70%。
穿山甲:味咸,性微寒;归肝,胃经。《滇南本草》:“治疥癞痈毒,破气行血,胸膈膨胀逆气,治膀胱疝气疼痛。”《本草纲目》:“除痰疟寒热,风痹强直疼痛,通经脉,下乳汁,消痈肿,排脓血,通窍杀虫。”活血散结,通经下乳,消痈溃坚。主血瘀经闭,症瘕,风湿痹痛,乳汁不下,痈肿,瘰疬
桂枝“辛,甘,性温;入膀胱、心、肺经。《本草衍义补遗》:“仲景治表用桂枝,非表有虚以桂补之;卫有风邪,故病自汗,以桂枝发其邪,卫和则表密汗自止,非桂枝能收汗而治之。”《本草纲目》:“麻黄遍彻皮毛,故专于发汗而寒邪散,肺主皮毛,辛走肺也。桂枝透达营卫,故能解肌而风邪去,脾主营,肺主卫,甘走脾,辛走肺也。”《本草汇言》:“桂枝,散风寒,逐表邪,发邪汗,止咳嗽,去肢节间风痛之药也。气味虽不离乎辛热,但体属枝条,仅可发散皮毛肌腠之间,游行臂膝肢节之处。”功能发汗解肌,温经通脉,助阳化气,散寒止痛。散寒解表;温通经脉;通阳化气。主风寒表证;寒湿痹痛;四肢厥冷;经闭腹痛;症瘕结块;胸痹;心悸;小便不利。用于风寒感冒,脘腹冷痛,血寒经闭,关节痹痛,痰饮蓄水,水肿,心悸,奔豚。
甘草:性味甘,平。入脾、胃、肺经。《本经》曰:“主五脏六府寒热邪气,坚筋骨,长肌肉,倍力,金疮肿,解毒”。《药性论》曰:“主腹中冷痛,治惊痫,除腹胀满;补益五脏;制诸药毒;养肾气内伤,令痿;主妇人血沥腰痛;虚而多热;加而用之”。可益气补中,缓急止痛,润肺止咳,泻火解毒,调和诸药。主倦怠食少,肌瘦面黄,心悸气短,腹痛便溏,四肢挛急疼痛,脏躁,咳嗽气喘,咽喉肿痛,痈疮肿痛,小儿胎毒,及药物、食物中毒。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。西医药理发现,甘草剂有抗炎和抗变态反映的功能,因此在西医临床上主要作为缓和剂。缓解咳嗽,祛痰,治疗咽痛喉炎;甘草或甘草次酸有去氧皮质酮类作用,对慢性肾上腺皮质功能减退症有良好功效;甘草制剂能促进胃部粘液形成和分泌,延长上皮细胞寿命,有抗炎活性,常用于慢性溃疡和十二指肠溃疡的治疗;甘草的黄酮具有消炎、解痉和抗酸作用;甘草也是人丹的主要原料之一。
当归:味甘、辛、苦,性温,入肝、心、脾经,《注解伤寒论》:“脉者血之府,诸血皆属心,凡通脉者必先补心益血,故张仲景治手足厥寒,脉细欲绝者,用当归之苦温以助心血。”《本草新编》:“当归,味甘辛,气温,可升可降,阳中之阴,无毒。虽有上下之分,而补血则一。入心、脾、肝三脏。但其性甚动,入之补气药中则补气,入之补血药中则补血,无定功也。”具有补血活血,调经止痛、润汤通便的作用,用于血虚萎黄、眩晕心悸、月经不调、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡等证。①抗缺氧作用;②调节机体免疫功能、具有抗癌作用;③护肤美容作用;④补血活血作用;⑤抑菌、抗动脉硬化作用。现代研究表明,当归具有调节机体免疫功能、补血活血,抑菌等作用。其能改善子宫的血液循环、减轻盆腔充血,缓解痛经,此外,当归能够增强机体的免疫力。
生地:甘,寒;归心,肝,肾经。《神农本草经》:“味甘,寒。主治折跌,绝筋,伤中,逐血痹,填骨髓,长肌肉。作汤除寒热积聚,除痹。生者尤良。”清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、凉血、止血活血。生地性寒,功能为凉血清热、滋阴补肾、生津止渴,常用于治疗骨蒸痨热、咽喉燥痛、痰中带血等症。由将生地以砂仁、酒、陈皮为辅料,反复蒸晒至颜色变黑,质地柔软即为了熟地,而有熟地制成的六味地黄丸,就是著名的补肾良药,临床还常用于慢性肾炎、高血压、神经衰弱、肺结核等病的治疗。
牛膝:味苦,酸,性平;归肝,肾经。《日华子本草》:“治腰膝软怯冷弱,破症结,排脓止痛,产后心腹痛并血运,落胎,壮阳。”《滇南本草》:“治疔疮、痈疽,敷患处。亦能打胎。同猪肉煨食之,能明目。”具有补肝肾,强筋骨,活血通经,引火(血)下行,利尿通淋的功效,怀牛膝功偏滋补肝肾,壮腰膝:用于肝肾不足引起的筋骨酸软、腰膝疼痛。川牛膝以活血通经,祛风湿见长:用于血瘀经闭及风湿痛。本品性善下行,专治上炎之火及上部出血,故常用于虚火上炎或血热上冲之目赤、咽肿、吐血、衄血等症。中医认为,其性味苦甘酸平,具有活血通经,补肝肾,强筋骨,利尿通淋,引血(火)下行之功效,常用于治疗瘀血阻滞的经闭、痛经、月经不调、产后腹痛等妇科病,跌打损伤,肾虚之腰膝酸痛、下肢无力,尿血,小便不利,尿道涩痛以及火热上炎引起的头痛、眩晕、吐血、衄血等证。
地龙:清热,镇痉,利尿,解毒。用于热病惊狂、小儿惊风、咳喘、头痛目赤、咽喉肿痛、小便不通、风湿关节疼痛,半身不遂地龙菜等症。外用涂丹毒、漆疮等症。预先腹腔注射地龙注射液10g/kg,对蒙古沙土鼠一测预总动脉结扎造成的缺血性脑卒中具有一定的预防作用,可减轻缺血性脑卒中的症状;小鼠每日灌服地龙提取物l1mg/只,连续58d,对移植的肉瘤S180。有明显的抑制作用,不仅瘤体明显减少,且可延长小鼠的生存期。常规剂量毒性小,过量使用可出现头痛、头昏,血压先升后降、腹痛、呼吸困难、消化道出血。
川芎:味辛,性温;归肝、胆、心经。《神农本草经》:“主中风入脑头痛、寒痹,筋脉缓急,金疮,妇人血闭无子。”《日华子本草》:“治一切风,一切气,一切劳损,一切血,补五劳,壮筋骨,调众脉,破症结宿血,养新血,长肉,鼻洪,吐血及溺血,痔瘘,脑痈发背,瘰疬瘿赘,疮疥,及排脓消瘀血。”气香升散。具有活血行气,祛风止痛的功效。主治月经不调,痛经,经闭,难产,胞衣不下,产后恶露腹痛,肿块,心胸胁疼痛,跌打损伤肿痛,头痛眩晕目暗,风寒湿痹 ,肢体麻木,痈疽疮疡。用于感冒头痛,偏正头痛等症。川芎辛香善升,能上行头目巅顶,具有祛风止痛作用,为治头风头痛要药。此外,临床常用该品治疗冠心病心绞痛。川芎辛温香燥,走而不守,既能行散,上行可达巅顶;又入血分,下行可达血海。川芎嗪能扩张冠状动脉,增加冠状动脉血流量,改善心肌的血氧供应,并降低心肌的耗氧量;川芎嗪可扩张脑血管,降低血管阻力,显著增加脑及肢体血流量,改善微循环;能降低血小板表面活性,抑制血小板凝集,预防血栓的形成。
五灵脂:甘,温。活血散瘀,炒炭止血。用于心腹淤血作痛,痛经,血瘀经闭,产后淤血腹痛;炒炭治崩漏下血;外用治跌打损伤,蛇、虫咬伤。五灵脂苦泄温通,“通利气脉”,“通则不痛。”故《本草经疏》谓之“血滞经脉,气不得行,攻刺疼痛等证,在所必用。”
蒲黄:味甘、微辛、性平;入肝、心、脾经。功用止血,祛瘀,利尿,主治吐血咯血衄血,备痢,便血、崩漏,外伤出血,心腹疼痛,经闭腹痛、产后瘀痛、痛经,跌扑肿痛,血淋涩痛、带下、重舌,口疮、聤耳、阴下湿痒。蒲黄提取液对离体兔心有明显增加冠脉流量的作用。蒲黄提取物对离体蛙心、兔心有可逆性的抑制作用,高浓度时使心脏停搏于舒张状态;并有降低家兔血压的作用。蒲黄对心脏的抑制作用,可能与蒲黄中所含的槲皮素(亦是胆碱脂酶抑制剂)有关。蒲黄能防止喂饲高脂动物的血清胆固醇水平增高,并能增加喂饲高脂家兔的粪便胆固醇。蒲黄煎液及其提取物总黄酮、有机酸、多糖等对ADP、花生四烯酸及胶原诱、导家兔体内、外血小板聚集功能均有明显抑制作用,其中以总黄酮作用最强,说明黄酮类化合物为蒲黄抗血小板聚集的主要有效成分。
天仙藤:苦,温;入肝、脾、肾经。《本草图经》:"解风劳。得麻黄则治伤寒发汗,与大黄同服堕胎气。"《本草再新》:"凉血活血,去风利湿,走经络,兼治腰腿肿疼。"行气化湿,活血止痛。治胃痛,疝气痛,妊娠水肿,产后血气腹痛,风湿疼痛。 行气活血,止痛,利尿。妊娠水肿,胸腹痛,疝痛,风湿痛。天仙藤,流气活血,治一切诸痛之药也。人身之气,顺则和平,逆则痛闷作矣。如杨氏《直指方》天仙藤治痰注臂痛,气留疝痛,瘕聚,奔豚腹痛,产后血气腹痛,他如妊娠水肿,面浮气促,男子风劳,久嗽不愈,悉以此药治之,无不寝安。盖谓其善于流行血气故也。观书所论主治,止属妊娠子肿、腹痛、风痨等症,而于他症则未及焉。即其所治之理,亦不过因味苦主于疏泄,性温得以通活,故能活血通道,而使水无不利,风无不除,血无不活,痛与肿均无不治故也。
乳香:辛苦,温。入心、肝、脾经。《本草拾遗》:“疗耳聋,中风口噤,妇人血气,能发酒,理风冷,止大肠泄澼,疗诸疮令内消。”《本草纲目》:“消痈疽诸毒,托里护心,活血定痛,伸筋,治妇人难产,折伤。”调气活血,定痛,追毒。治气血凝滞、心腹疼痛,痈疮肿毒,跌打损伤,痛经,产后瘀血刺痛。以乳香为首味药的子宫丸比多种抗菌素有更强烈的抑菌作用,且能有效地杀灭滴虫。故凡心胃胁腹肢体关节诸疼痛皆能治之。又善治女子行经腹疼,产后瘀血作痛,月事不以时下。其通气活血之力,又善治风寒湿痹,周身麻木,四肢不遂及一切疮疡肿疼,或其疮硬不疼。外用为粉以敷疮疡,能解毒,消肿、生肌、止疼,虽为开通之品,不至耗伤气血,诚良药也.
刺蒺藜:《名医别录》:“主身体风痒,头痛、咳逆伤肺,肺痿,止烦、下气;小儿头疮,痈肿阴癀,可作摩粉。”散风,明目,下气,行血。治头痛,身痒,目赤肿翳,胸满,咳逆,症瘕,乳难,痈疽,瘰疬。蒺藜水浸液、乙醇-水浸出液和30%乙醇浸出液对麻醉动物有降压作用.醇提取物对狗的降压作用是通过胆碱能神经实现的,阿托品以及切断双侧迷走神经能阻断此作用。蒺藜皂甙有扩张冠状动脉、改善冠状动脉循环、增强心脏收缩力、减慢心律的作用,亦能抑制血小板聚集,预防垂体后叶素及异丙肾上腺素所诱发的缺血性心电图变化,有抗心肌缺血和缩小心肌梗死范围的作用。蒺藜水煎剂及其灰分的水提取物有利尿作用,其利尿作用主要是由于钾盐的存在。水提取部分对大鼠度体肠管有对抗乙酰胆碱收缩的作用,生物碱部分亦能对抗大鼠离体肠管及蛙腹直肌因乙酰胆碱所引起的收缩作用。
王不留行:苦,平;归肝,胃经。《本草新编》:“王不留行,其性甚急,下行而不上行者也。凡病逆而上冲者用之可降,故可恃之以作臣使之用也。但其性过速,宜暂而不宜久,又不可不知也。或问:王不留行之可下乳,是亦可上行之物也。不知乳不能下而下之,毕竟是下行,而非上行也。上中焦有可下者,皆可下通,非止行于下焦而不行于上焦也。”能行血调经、消肿止痛、活血通乳、催生下乳、产后胸腺疏通。用于血瘀经闭,痛经,难产;产后乳汁不下,乳痈肿痛;热淋,血淋,石淋。王不留行有抗早孕,抗着床作用,亦有调节生理功能,影响体内代谢的作用.亦有报告认为,王不留行煎剂对大鼠离体子宫有收缩作用;其乙醇提取液作用尤强.
月季花:月季花不仅是花期绵长、芬芳色艳的观赏花卉,而且是一味妇科良药。中医认为,月季味甘、性温,入肝经,有活血调经、消肿解毒之功效。由于月季花的祛瘀、行气、止痛作用明显,故常被用于治疗肝郁血滞,月经不调、痛经、闭经及胸胁胀痛。跌打损伤,瘀肿疼痛,痈疽肿毒,瘰疬。临床报道,妇女出现闭经或月经稀薄、色淡而量少、小腹痛,兼有精神不畅和大便燥结等,或在月经期出现上述症状,用胜春汤治疗效果好。
虻虫:味苦,微咸,性凉。《本经》:“主逐瘀血,破下血积、坚痞、症瘕,寒热,通利血脉及九窍。”虻虫在体外有较弱的抗凝血酶作用,体外和体内均有活化纤溶系统的作用。虻虫水煎剂对小鼠离体回肠运动有明显抑制作用。虻虫提取物B、C和D组分80mg/kg,分别腹腔注射,均 能明显抑制大鼠角叉菜胶性足肿胀,其B组分作用较强,后者静注10-20mg/kg的阿司匹林。虻虫提取物A或B组分100mg/kg灌胃,能明显对抗苯醌(phenylquinone)所致小鼠扭体反应,其B 组分作用较强。虻虫对家兔离体子宫有兴奋作用,对内毒素所致肝出血性坏死病灶的形成有显著的抑制作用,虻虫醇提取物有明显溶血作用。
黄芪:甘,微温;归肺、脾、肝、肾经。《本草备要》:“黄芪,生用固表,无汗能发,有汗能止;炙用补中,益元气,壮脾胃。生血,生肌,排脓内托,疮痈圣药。痘症不起,阳虚无热者宜之。”《本草正义》:“黄芪,补益中土,温养脾胃,凡中气不振,脾土虚弱,清气下陷者最宜。其皮直达人之肤表肌肉,固护卫阳,充实表分,是其专长,所以表虚诸病,最为神剂。”功用固表敛汗,利水消肿,托疮排脓,通调水道。黄芪使心脏收缩能力增强,能改善全身的血液循环,能扩张冠状动脉、肾血管及拳参末梢血管、使皮肤血液循环旺盛;能提高机体的非特异免疫力,有保肝和降低血糖的作用,对葡萄球菌、血溶性链球菌、肺炎双球菌、痢疾杆菌等有抑制作用。黄芪可显著影响脾淋巴细胞信息传导,实现免疫调节作用。可用于高血压病,缺血性心脏病,急性肾小球肾炎,胃溃疡,银屑病,糖尿病,骨质疏松。
山药:味甘,性平,入肺、脾、肾经,具有健脾补肺、益胃补肾、固肾益精、聪耳明目、助五脏、强筋骨、长志安神、延年益寿的功效,主治脾胃虚弱、倦怠无力、食欲不振、久泄久痢、肺气虚燥、痰喘咳嗽、肾气亏耗、腰膝酸软、下肢痿弱、消渴尿频、遗精早泄、带下白浊、皮肤赤肿、肥胖等证。麸炒山药补脾健胃。用于脾虚食少,泄泻便溏,白带过多。
山茱萸:酸、涩、微温;入肝、心、肾三经。《名医别录》载:“山茱萸微温,无毒。主治肠胃风邪,寒热疝瘕,……耳聋,下气,出汗,益精,安五脏,通九窍,止小便利。”《汤液本草》:“滑则气脱,涩剂所以收之,山茱萸止小便利,秘精气取其味酸涩以收滑也。”补肝肾,涩精气,固虚脱。治腰膝酸痛,眩晕,耳鸣,阳痿,遗精,小便频数,肝虚寒热,虚汗不止,心摇脉散。山茱萸注射液2~8g/kg给猫静脉滴注, 能增强其心肌收缩性,提高心脏效率,扩张外周血管,明显增强心脏泵血功能, 使血压升高。《本草经集注》:“蓼实为之使。恶桔梗、防风、防己。”
西洋参:味甘、微苦,性寒。能补气,养阴,清火。含十余种人参皂甙、少量挥发油、糖类、氨基酸、无机元素等。能调节中枢神经系统的兴奋与抑制,以抑制较为突出;能抗疲劳、抗缺氧、增强机体适应能力;有抗心律失常、抗心肌缺血、增强心肌收缩力的作用;有促进肾上腺皮质激素分泌的作用;能增强机体免疫功能;有抗利尿及止血作用。西洋参中的皂甙可以有效增强中枢神经,达到静心凝神、消除疲劳、增强记忆力等作用,可适用于失眠、烦躁、记忆力衰退及老年痴呆等症状。西洋参作为补气保健首选药材,可以促进血清蛋白合成、骨髓蛋白合成、器官蛋白合成等,提高机体免疫力,抑制癌细胞生长,有效抵抗癌症。长服西洋参可以降低血液凝固性、抑制血小板凝聚、抗动脉粥样硬化并促进红血球生长,增加血色素。西洋参可以降低血糖、调节胰岛素分泌、促进糖代谢和脂肪代谢,对治疗糖尿病有一定辅助作用。
土鳖虫 :性寒、味咸,入心肝脾三经。《神农本草经》:“蛰虫,味咸寒。主心腹寒热、血积症瘕,破坚、下血闭,一名地鳖。生川泽。”《名医别录》:“生河东川泽及沙中,人家墙壁下、土中湿处。十月采,暴干。”《外科大成》:“治走马牙疳,牙落鼻崩,久不愈者。”具有逐瘀、破积、通络、理伤以及接骨续筋、消肿止痛、下乳通经等功效,是理血伤科要药,适用于癌瘕积聚、血滞经闭、产后瘀血腹痛、跌打损伤、木舌、重舌等病症。提取液及水提醇沉液分别有抗血栓形成和溶解血栓的作用;提取物可抑制血小板聚集和粘附率,减少聚集数;总生物碱可提高心肌和脑对缺血的耐受力,并降低心、脑组织的耗氧量;水煎液具有调脂作用,能延缓动脉粥样硬化的形成;提取物可抑制D-半乳糖所致的肝损害而有保肝作用。
蜂房:甘,平;归胃、肝、肺二经。《日华子本草》:“治牙齿疼,痢疾,乳痈,蜂叮,恶疮。”《神农本草经》:“主惊痫瘈疭,寒热邪气,癫疾,肠痔。”祛风,攻毒,杀虫,止痛,抗过敏。龋齿牙痛,疮疡肿毒,乳痈,瘰疬,皮肤顽癣,鹅掌风,过敏性体质。本品能攻毒杀虫,攻坚破积,为外科常用之品。本品质轻且性善走窜,能祛风止痛、止痒而奏效。近代还常用露蜂房治疗流行性腮腺炎、急性乳腺炎和其他化脓性感染,能去腐生肌、消炎止痛,并促进创口早期愈合。此外还有祛风止痛之效,能治疗风痹。
莪术:辛、苦,温。归肝、脾经。本品功效与三棱相似,但温通力较大,可治疗血滞经闭腹痛、腹部包块、积聚。能行气消积止痛,用于饮食积滞、胸腹满闷作痛。还可破血祛瘀,妇女闭经,或痰湿淤血凝结而成的症瘕癖块。莪术油制剂在体外对小鼠艾氏腹水癌细胞、615纯系小鼠的L615白血病及腹水型肝癌细胞等多种瘤株的生长有明显抑制和破坏作用。莪术根茎的醇浸膏及其有效成分(单萜类和倍半萜类化合物)对大鼠、小鼠有非常显着的抗早孕作用,对犬也有一定抗着床效果。
丹皮:味苦、辛,性微寒,入心、肝、肾经。《本经》:"主寒热,中风瘈疭、痉、惊痫邪气,除症坚瘀血留舍肠胃,安五脏,疗痈疮。"《日华子本草》:"除邪气,悦色,通关腠血脉,排脓,通月经,消扑损瘀血,续筋骨,除风痹,落胎下胞,产后一切冷热血气。"。《本草纲目》:“滋阴降火,解斑毒,利咽喉,通小便血滞。后人乃专以黄蘖治相火,不知丹皮之功更胜也。赤花者利,白花者补,人亦罕悟,宜分别之。”具有清热凉血、活血散瘀的作用,主要用于治疗温热病热入血分、发斑、吐衄,热病后期热伏阴分发热、阴虚骨蒸潮热、血滞经闭、痛经、痈肿疮毒、跌扑伤痛、风湿热痹等证。善清血,而又活血,因而有凉血散瘀的功效,使血流畅而不留瘀,血热清而不妄行。故对血热炽盛、肝肾火旺及瘀血阻滞等症,都恃为要药。牡丹皮对麻醉犬心能增加冠脉血流量,减少心输出量,降低左室作功的作用。丹皮酚对口服伤寒、副伤寒菌苗引起的小鼠发热有解热作用,并降低正常小鼠体温。
羊红膻:味甘,辛,性温;归心、肾、肺、脾经。《陕西中草药》:“祛寒宣肺,祛风解毒,活血散瘀,消肿止痛。”《中药通报》:“治疗产后虚弱,阳痿不育,风寒感冒,痰饮咳嗽等。”温中散寒、温肾助阳,活血化瘀;健脾益气,养心安神,止咳祛痰。主治克山病,心改建,气短,咳喘。用于脾胃虚寒所致脘腹冷痛、呕吐、泄泻等。用治风寒袭肺、肺气失宣、咳嗽咳痰、胸闷喘息。初步药理实验证明根及全草有抗凝血的作用。全草尚能扩张冠状动脉、降低冠脉阻力,有降压作用,能降低心肌氧耗量。黄酮苷能增强心肌及脑组织呼吸酶的活性;其水煎醇沉制剂有明显的降压作用,并具有一定强壮作用。
瓦楞子:咸,平。归肺、胃、肝经。消痰化瘀,软坚散结,制酸止痛。用于顽痰积结,粘稠难咯,瘿瘤,瘰疬,瘕痞块,胃痛泛酸。瓦楞子味咸软坚,消顽痰,散郁结。治瘿瘤、痰核,常与海藻,昆布等同用,如《证治准绳疡医》含化丸。现代以此用治肝脾肿大及消化道肿瘤等。用于胃痛泛酸。
自然铜:《日华子本草》:“排脓,消瘀血,续筋骨,治产后血邪,安心,止惊悸。以酒磨服。”《本草纲目》:“自然铜,接骨之功,与铜屑同,不可诬也。但接骨之后,不可常服,即便理气活血可尔。”在试管内,自然钢对供试的多种病原性真菌均有不同程度的抗真茵作用,尤其对石膏样毛藓菌、土曲霉菌等丝状真茵作用较强。钢能提高赖氨酸氧化酶的活性,使胶原纤维韧性加强,胶原不溶性增加,从而增强生物力学强度,而应力刺激x可促进新骨生成。故自然铜有促进骨折愈合的作用。此外,自然铜尚可促进骨髓自身及其周围血液中网状细胞和血色素增生。
秋海棠根:性味①《贵州草药》:"性平,味酸涩。"②《陕西中草药》:"味苦涩酸,性寒。"功能主治活血化瘀,止血,清热。治跌打损伤,吐血、咯血,痢疾,月经不调,崩漏,带下,淋浊,喉痛。①《分类草药性》:"治吐血,跌打损伤。"②《贵州民间方药集》:"止吐血、咯血、刀伤出血。"③《贵州草药》:"活血化瘀,凉血止血。"④《陕西中草药》:"活血散瘀,清热,止血止痛。治跌打损伤,吐血,衄血,胃溃疡,痢疾,肺痈,崩漏,白带,月经不调。"⑤江西《草药手册》:"行气行血,消肿止痛,镇痉,治瘰疬。"
牛马藤:性味①《四川中药志》:"甘,温,无毒。"②《中药鉴别手册》:"性温,味苦。"功能主治行血补血,通经活络。治风湿疼痛,四肢麻木,贫血,月经不调。①《草木便方》:"活血化瘀,舒筋,利关节。治腰脊痛。"②《分类草药性》:"治寒脾风,风湿麻木,筋骨疼痛,消肿。"③江西《草药手册》:"治妇女经闭,膝盖骨痛。"
其中,所述原料药材的重量份数比为:柴胡10-26重量份、桃仁12-20重量份、穿山甲13-25重量份、桂枝10-20重量份、甘草15-25重量份、当归10-24重量份、生地12-28重量份、牛膝10-20重量份、地龙12-24重量份、川芎10-20重量份、五灵脂12-23重量份、蒲黄10-20重量份、天仙藤15-22重量份、乳香10-20重量份、刺蒺藜12-23重量份、王不留行10-20重量份、月季花12-24重量份、虻虫3-8重量份、黄芪10-20重量份、山药5-10重量份、山茱萸10-20重量份、西洋参12-25重量份、土鳖虫3-8重量份、蜂房10-20重量份、莪术3-7重量份、丹皮10-20重量份、羊红膻10-18重量份、瓦楞子12-24重量份、自然铜10-20重量份、秋海棠根10-18重量份、牛马藤12-25重量份。
其中,所述原料药材的重量份数比为:柴胡20-26重量份、桃仁15-20重量份、穿山甲20-25重量份、桂枝16-20重量份、甘草20-25重量份、当归20-24重量份、生地20-28重量份、牛膝15-20重量份、地龙20-24重量份、川芎16-20重量份、五灵脂20-23重量份、蒲黄16-20重量份、天仙藤18-22重量份、乳香16-20重量份、刺蒺藜18-23重量份、王不留行16-20重量份、月季花20-24重量份、虻虫6-8重量份、黄芪16-20重量份、山药8-10重量份、山茱萸16-20重量份、西洋参20-25重量份、土鳖虫6-8重量份、蜂房16-20重量份、莪术5-7重量份、丹皮15-20重量份、羊红膻15-18重量份、瓦楞子20-24重量份、自然铜16-20重量份、秋海棠根15-18重量份、牛马藤20-25重量份。
其中,所述原料药材的重量份数比为:柴胡10重量份、桃仁12重量份、穿山甲13重量份、桂枝10重量份、甘草15重量份、当归10重量份、生地12重量份、牛膝10重量份、地龙12重量份、川芎10重量份、五灵脂12重量份、蒲黄10重量份、天仙藤15重量份、乳香10重量份、刺蒺藜12重量份、王不留行10重量份、月季花12重量份、虻虫3重量份、黄芪10重量份、山药5重量份、山茱萸10重量份、西洋参12重量份、土鳖虫3重量份、蜂房10重量份、莪术3重量份、丹皮10重量份、羊红膻10重量份、瓦楞子12重量份、自然铜10重量份、秋海棠根10重量份、牛马藤12重量份。
其中,所述原料药材的重量份数比为:柴胡26重量份、桃仁20重量份、穿山甲25重量份、桂枝20重量份、甘草25重量份、当归24重量份、生地28重量份、牛膝20重量份、地龙24重量份、川芎20重量份、五灵脂23重量份、蒲黄20重量份、天仙藤22重量份、乳香20重量份、刺蒺藜23重量份、王不留行20重量份、月季花24重量份、虻虫8重量份、黄芪20重量份、山药10重量份、山茱萸20重量份、西洋参25重量份、土鳖虫8重量份、蜂房20重量份、莪术7重量份、丹皮20重量份、羊红膻18重量份、瓦楞子24重量份、自然铜20重量份、秋海棠根18重量份、牛马藤25重量份。
为了解决上述技术问题,本发明还提供了一种治疗淤血蓄结型子宫肌瘤的中药组合物的制备方法,其中,所述中药组合物的剂型为胶囊剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~5倍的醇浓度为80~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得350目~400目的超微细粉;
第三步,在第二步获得的超微细粉中依次加入滑石粉、硬脂酸镁,进行混匀处理,即得胶囊内容物;所述超微细粉、硬脂酸镁和滑石粉的重量比为100∶0.02~0.1:0.01~0.1,将所述胶囊内容物装入胶囊壳体中,即得胶囊剂。
其中,所述中药组合物的剂型为片剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得250目~400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.01~0.3倍的微晶纤维素、0.05~0.1倍乳糖、0.02~0.2倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.001~0.01倍硬脂酸镁,整粒,压片,制成。
所述中药组合物的剂型为:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、蜜丸剂、散剂、丹剂、溶液剂、注射剂、栓剂、硬膏剂、糖浆剂、散剂、灌肠剂和贴剂。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1 胶囊剂
柴胡10g、桃仁12g、穿山甲13g、桂枝10g、甘草15g、当归10g、生地12g、牛膝10g、地龙12g、川芎10g、五灵脂12g、蒲黄10g、天仙藤15g、乳香10g、刺蒺藜12g、王不留行10g、月季花12g、虻虫3g、黄芪10g、山药5g、山茱萸10g、西洋参12g、土鳖虫3g、蜂房10g、莪术3g、丹皮10g、羊红膻10g、瓦楞子12g、自然铜10g、秋海棠根10g、牛马藤12g。
其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量5倍的醇浓度为80%的乙醇,加热回流3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2倍的醇浓度为85%的乙醇,加热回流3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎2小时,粉碎,过筛,获得350目的超微细粉;
第三步,在第二步获得的超微细粉中依次加入滑石粉、硬脂酸镁,进行混匀处理,即得胶囊内容物;所述超微细粉、硬脂酸镁和滑石粉的重量比为100∶0.02:0.01,将所述胶囊内容物装入胶囊壳体中,即得胶囊剂。
实施例2 片剂
柴胡26g、桃仁20g、穿山甲25g、桂枝20g、甘草25g、当归24g、生地28g、牛膝20g、地龙24g、川芎20g、五灵脂23g、蒲黄20g、天仙藤22g、乳香20g、刺蒺藜23g、王不留行20g、月季花24g、虻虫8g、黄芪20g、山药10g、山茱萸20g、西洋参25g、土鳖虫8g、蜂房20g、莪术7g、丹皮20g、羊红膻18g、瓦楞子24g、自然铜20g、秋海棠根18g、牛马藤25g。
其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2倍的醇浓度为85%的乙醇,加热回流1小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1倍的醇浓度为80%的乙醇,加热回流1小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1小时,粉碎,过筛,获得250目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.01倍的微晶纤维素、0.05倍乳糖、0.02倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.001倍硬脂酸镁,整粒,压片,制成。
实施例3 汤剂
柴胡16g、桃仁20g、穿山甲15g、桂枝10g、甘草15g、当归24g、生地28g、牛膝10g、地龙24g、川芎20g、五灵脂23g、蒲黄20g、天仙藤22g、乳香20g、刺蒺藜23g、王不留行20g、月季花24g、虻虫8g、黄芪20g、山药10g、山茱萸15g、西洋参20g、土鳖虫5g、蜂房15g、莪术5g、丹皮14g、羊红膻12g、瓦楞子16g、自然铜15g、秋海棠根15g、牛马藤18g。
其制备方法为:
将所述原料药材混合放入紫砂锅中,加入清水,至清水浸过药材上表面3cm,浸泡5小时;将紫砂锅置于火上,武火煮沸后,改用文火慢煎50分钟至药液的剂量为200ml,过滤,得滤液a,备用;将剩余药渣再次加入清水,至清水浸过药材上表面3cm,浸泡10小时;将紫砂锅置于火上,武火煮沸后,改用文火慢煎35分钟至药液的剂量为200ml,过滤,得滤液b,将滤液a和滤液b混合即可得汤剂。
药物的毒性试验
①急性毒性试验:以本发明实施例1的胶囊剂为对象,临床日用量的150倍给白鼠大肠内投药,观察7日。结果所有动物健存,其活动、饮食、毛发、排泄物未发现异常,未见毒性反应。急性毒性试验证明,该药没有毒性作用和不良反应,临床应用安全可靠。
②长期毒性试验:将本发明实施例2的片剂对小鼠按7.5、15和42g生药/kg连续用药12周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明中药组合物对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药12周及停药4周后,小鼠各脏器均无明显改变。说明本发明中药组合物对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
临床试验
临床治疗:选择2011年7月-2012年7月期间,我院接收的淤血蓄结型子宫肌瘤患者共计200例。其中,200例患者中,年龄35岁以下的病例患者有60例,年龄35-45岁的病例患者80例,年龄45岁以上的病例患者有60例。患者的月经周期平均为28天。患者中,不同程度的患有淤血蓄结型子宫肌瘤,症状为月经量多如涌、色紫有血块、下腹有刺痛感不能按住,有的患者月经来的时候持续时间长,很难干净,舌紫黯有瘀斑,脉沉涩。将该200例患者随机分为治疗一组、治疗二组、治疗三组和对照组各50例,来进行治疗对比。四组患者在年龄、病情轻重方面比较差异无统计学意义,具有可比性,并根据病情的轻重门诊治疗。
诊断标准
1、月经过多,经期延长或不规则出血,下腹可出现硬块,少数有疼痛及压迫症状,或伴盆血。
2、子宫增大,质硬。
3、探测宫腔增长或变形。
4、诊刮时宫腔内触及凸起面。
5、B型超声及/或子宫镜检查可协助诊断。
治疗方法
治疗一组:本组50人使用本发明的实施例1的胶囊剂进行治疗。每日3次,每次2粒,药剂量为0.25g/粒,一个月经周期一个疗程,治疗进行3个疗程。
治疗二组:本组50人使用本发明的实施例2的片剂进行治疗。每日3次,每次一片,每片0.4g,一个月经周期一个疗程,治疗进行3个疗程。
治疗三组:本组50人使用本发明的实施例3的汤剂进行治疗。每日1次,每次40ml,一个月经周期一个疗程,治疗进行3个疗程。
对照组:本组50人使用宫瘤消胶囊进行治疗。口服,一次3—4粒,一日3次,一个月经周期一个疗程,连续服用3个疗程,治疗进行3个疗程。
疗效评定
痊愈:B超查:子宫肌瘤已全部消失,或肌瘤钙化斑,或钙化包膜;基本痊愈:子宫肌瘤体积缩小2/3以上,肌瘤死亡,瘤囊待吸收需要时间;有效:子宫肌瘤体积缩小不及2/3,肌瘤没有死亡,需继续治疗;无效:治疗前后,体积未见缩小。
治疗结果
表1为各组的治疗效果对比
| 组别 | 痊愈 | 基本痊愈 | 有效 | 无效 |
| 治疗一组 | 47(94%) | 2(4%) | 1(2%) | 0(0%) |
| 治疗二组 | 48(96%) | 1(2%) | 1(2%) | 0(0%) |
| 治疗三组 | 46(92%) | 3(6%) | 1(2%) | 0(0%) |
| 对照组 | 30(60%) | 3(6%) | 5(10%) | 12(%) |
由表1可以看出,三个治疗组的治疗效果明显都要好于对照组,由此可知本发明的中药组合物,治疗淤血蓄结型子宫肌瘤,疗效好,疗效确切。
表2为各组的痊愈复发情况对比(跟进半年观察)
| 组别 | 痊愈人数 | 复发情况 |
| 治疗一组 | 47 | 0(0%) |
| 治疗二组 | 48 | 0(0%) |
| 治疗三组 | 46 | 0(0%) |
| 对照组 | 30 | 10(33.33%) |
由表2可以看出,三个治疗组的治疗痊愈人数,在随访观察中复发情况没有,而对照组有一部分出现复发。由此可知,本发明的中药组合物,在治疗淤血蓄结型子宫肌瘤上,治疗效果好,不易复发。
表3为各组的副作用对比
| 组别 | 副作用出现人数 | 副作用出现率 |
| 治疗一组 | 0 | 0 |
| 治疗二组 | 0 | 0 |
| 治疗三组 | 0 | 0 |
| 对照组 | 5 | 10% |
由表3可以看出,三个治疗组的病人在治疗过程中没有出现副作用,而对照组患者在治疗过程中出现副作用,出现一些过敏反应。由此可知,本发明的中药组合物,在治疗淤血蓄结型子宫肌瘤上,治疗不会产生副作用,安全有效。
综上所述,本发明的中药组合物,在治疗淤血蓄结型子宫肌瘤上,治疗效果好,疗效快,疗效确切,安全有效,无复发,并且无副作用。
典型:李某,女,48岁,患有淤血蓄结型子宫肌瘤,症状表现为:月经量多如涌、色紫有血块、下腹有刺痛感不能按住,确诊为淤血蓄结型子宫肌瘤。使用本发明实施例2的片剂进行治疗。每日3次,每次一片,每片0.4g,一个月经周期一个疗程,治疗进行3个疗程。服药过程中,李某未出现不良反应,服药之后,痊愈,并且后期跟进观察半年,没有再复发。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种治疗淤血蓄结型子宫肌瘤功能的中药组合物,其特征在于,所述中药组合物包括以下原料药材:柴胡、桃仁、穿山甲、桂枝、甘草、当归、生地、牛膝、地龙、川芎、五灵脂、蒲黄、天仙藤、乳香、刺蒺藜、王不留行、月季花、虻虫、黄芪、山药、山茱萸、西洋参、土鳖虫、蜂房、莪术、丹皮、羊红膻、瓦楞子、自然铜、秋海棠根、牛马藤。
2.根据权利要求1所述的中药组合物,其特征在于,所述原料药材的重量份数比为:柴胡10-26重量份、桃仁12-20重量份、穿山甲13-25重量份、桂枝10-20重量份、甘草15-25重量份、当归10-24重量份、生地12-28重量份、牛膝10-20重量份、地龙12-24重量份、川芎10-20重量份、五灵脂12-23重量份、蒲黄10-20重量份、天仙藤15-22重量份、乳香10-20重量份、刺蒺藜12-23重量份、王不留行10-20重量份、月季花12-24重量份、虻虫3-8重量份、黄芪10-20重量份、山药5-10重量份、山茱萸10-20重量份、西洋参12-25重量份、土鳖虫3-8重量份、蜂房10-20重量份、莪术3-7重量份、丹皮10-20重量份、羊红膻10-18重量份、瓦楞子12-24重量份、自然铜10-20重量份、秋海棠根10-18重量份、牛马藤12-25重量份。
3.根据权利要求1或2所述的中药组合物,其特征在于,所述原料药材的重量份数比为:柴胡20-26重量份、桃仁15-20重量份、穿山甲20-25重量份、桂枝16-20重量份、甘草20-25重量份、当归20-24重量份、生地20-28重量份、牛膝15-20重量份、地龙20-24重量份、川芎16-20重量份、五灵脂20-23重量份、蒲黄16-20重量份、天仙藤18-22重量份、乳香16-20重量份、刺蒺藜18-23重量份、王不留行16-20重量份、月季花20-24重量份、虻虫6-8重量份、黄芪16-20重量份、山药8-10重量份、山茱萸16-20重量份、西洋参20-25重量份、土鳖虫6-8重量份、蜂房16-20重量份、莪术5-7重量份、丹皮15-20重量份、羊红膻15-18重量份、瓦楞子20-24重量份、自然铜16-20重量份、秋海棠根15-18重量份、牛马藤20-25重量份。
4.根据权利要求1至3任一项所述的中药组合物,其特征在于,所述原料药材的重量份数比为:柴胡10重量份、桃仁12重量份、穿山甲13重量份、桂枝10重量份、甘草15重量份、当归10重量份、生地12重量份、牛膝10重量份、地龙12重量份、川芎10重量份、五灵脂12重量份、蒲黄10重量份、天仙藤15重量份、乳香10重量份、刺蒺藜12重量份、王不留行10重量份、月季花12重量份、虻虫3重量份、黄芪10重量份、山药5重量份、山茱萸10重量份、西洋参12重量份、土鳖虫3重量份、蜂房10重量份、莪术3重量份、丹皮10重量份、羊红膻10重量份、瓦楞子12重量份、自然铜10重量份、秋海棠根10重量份、牛马藤12重量份。
5.根据权利要求1至4任一项所述的中药组合物,其特征在于,所述原料药材的重量份数比为:柴胡26重量份、桃仁20重量份、穿山甲25重量份、桂枝20重量份、甘草25重量份、当归24重量份、生地28重量份、牛膝20重量份、地龙24重量份、川芎20重量份、五灵脂23重量份、蒲黄20重量份、天仙藤22重量份、乳香20重量份、刺蒺藜23重量份、王不留行20重量份、月季花24重量份、虻虫8重量份、黄芪20重量份、山药10重量份、山茱萸20重量份、西洋参25重量份、土鳖虫8重量份、蜂房20重量份、莪术7重量份、丹皮20重量份、羊红膻18重量份、瓦楞子24重量份、自然铜20重量份、秋海棠根18重量份、牛马藤25重量份。
6.根据权利要求1至5任一项所述的中药组合物,其特征在于,所述中药组合物的剂型为胶囊剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~5倍的醇浓度为80~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得350目~400目的超微细粉;
第三步,在第二步获得的超微细粉中依次加入滑石粉、硬脂酸镁,进行混匀处理,即得胶囊内容物;所述超微细粉、硬脂酸镁和滑石粉的重量比为100∶0.02~0.1:0.01~0.1,将所述胶囊内容物装入胶囊壳体中,即得胶囊剂。
7.根据权利要求1至5任一项所述的中药组合物,其特征在于,所述中药组合物的剂型为片剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得250目~400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.01~0.3倍的微晶纤维素、0.05~0.1倍乳糖、0.02~0.2倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.001~0.01倍硬脂酸镁,整粒,压片,制成。
8.一种权利要求1至5任一项所述的中药组合物的制备方法,其特征在于,所述中药组合物的剂型为胶囊剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~5倍的醇浓度为80~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得350目~400目的超微细粉;
第三步,在第二步获得的超微细粉中依次加入滑石粉、硬脂酸镁,进行混匀处理,即得胶囊内容物;所述超微细粉、硬脂酸镁和滑石粉的重量比为100∶0.02~0.1:0.01~0.1,将所述胶囊内容物装入胶囊壳体中,即得胶囊剂。
9.一种权利要求1至5任一项所述的中药组合物的制备方法,其特征在于,所述中药组合物的剂型为片剂,其制备方法为:
第一步,将所述中药各原料药材按比例混合,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为80~90%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得250目~400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.01~0.3倍的微晶纤维素、0.05~0.1倍乳糖、0.02~0.2倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.001~0.01倍硬脂酸镁,整粒,压片,制成。
10.如权利要求1至5任一项所述的中药制剂,其特征在于,所述中药组合物的剂型为:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、蜜丸剂、散剂、丹剂、溶液剂、注射剂、栓剂、硬膏剂、糖浆剂、散剂、灌肠剂和贴剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410669028.4A CN104324330A (zh) | 2014-11-20 | 2014-11-20 | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410669028.4A CN104324330A (zh) | 2014-11-20 | 2014-11-20 | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104324330A true CN104324330A (zh) | 2015-02-04 |
Family
ID=52399220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410669028.4A Pending CN104324330A (zh) | 2014-11-20 | 2014-11-20 | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104324330A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721582A (zh) * | 2015-03-27 | 2015-06-24 | 李佃场 | 一种治疗肾虚型月经过少的药物及其制备方法 |
| CN105770294A (zh) * | 2016-04-23 | 2016-07-20 | 包晓娜 | 一种治疗子宫肌瘤的中药组合物 |
| CN107496828A (zh) * | 2017-08-11 | 2017-12-22 | 成都市飞龙水处理技术研究所青白江第分所 | 一种治疗淤血蓄结型子宫肌瘤的丸剂药物及制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1907391A (zh) * | 2006-08-02 | 2007-02-07 | 胡彩芳 | 治疗血瘀型子宫肌瘤并发崩漏症的汤剂药物及制备方法 |
| CN102949698A (zh) * | 2012-11-29 | 2013-03-06 | 广西东兴市创新特色医药科技发展有限公司 | 一种治疗子宫肌瘤的药物及其制备方法 |
| CN103550697A (zh) * | 2013-10-31 | 2014-02-05 | 王运邵 | 一种治疗子宫肌瘤的中药 |
-
2014
- 2014-11-20 CN CN201410669028.4A patent/CN104324330A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1907391A (zh) * | 2006-08-02 | 2007-02-07 | 胡彩芳 | 治疗血瘀型子宫肌瘤并发崩漏症的汤剂药物及制备方法 |
| CN102949698A (zh) * | 2012-11-29 | 2013-03-06 | 广西东兴市创新特色医药科技发展有限公司 | 一种治疗子宫肌瘤的药物及其制备方法 |
| CN103550697A (zh) * | 2013-10-31 | 2014-02-05 | 王运邵 | 一种治疗子宫肌瘤的中药 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721582A (zh) * | 2015-03-27 | 2015-06-24 | 李佃场 | 一种治疗肾虚型月经过少的药物及其制备方法 |
| CN105770294A (zh) * | 2016-04-23 | 2016-07-20 | 包晓娜 | 一种治疗子宫肌瘤的中药组合物 |
| CN107496828A (zh) * | 2017-08-11 | 2017-12-22 | 成都市飞龙水处理技术研究所青白江第分所 | 一种治疗淤血蓄结型子宫肌瘤的丸剂药物及制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847063B (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
| CN103007234B (zh) | 一种治疗子宫内膜异位引起痛经的中药制剂及其制备方法 | |
| CN103432530B (zh) | 一种治疗子宫内膜异位症的中药组合物及其制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN103751633A (zh) | 一种治疗下肢静脉曲张的中药组合物及其制备方法 | |
| CN101095923B (zh) | 一种治疗宫外孕的中药 | |
| CN102846824B (zh) | 一种治疗寒湿血瘀阻络型糖尿病足的中药组合物及其制备方法 | |
| CN104147538A (zh) | 一种治疗湿热毒盛型糖尿病足的中药制剂及其制备方法 | |
| CN102847074B (zh) | 治疗强直性脊柱炎的瘀血痹通丸 | |
| CN104324330A (zh) | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 | |
| CN105250619A (zh) | 一种治疗内在性子宫内膜异位症的中药及其制备方法 | |
| CN103157062B (zh) | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 | |
| CN104043058A (zh) | 一种治疗肾虚型腰椎间盘突出的中药制剂及其制备方法 | |
| CN104758754A (zh) | 一种治疗肾气虚衰型前列腺增生的药物及制备方法 | |
| CN104771637A (zh) | 治疗胆结石的利胆排石剂及制备方法 | |
| CN103989969A (zh) | 用于治疗风寒痹阻型神经根型颈椎病的中药及其制备方法 | |
| CN104306612A (zh) | 一种治疗痔疮的外用熏洗液 | |
| CN104257871B (zh) | 用于治疗湿热毒蕴型急性网状淋巴管炎的药物组合物及其制备方法 | |
| CN103751467A (zh) | 一种治疗腰背筋膜炎的中药组合物及其制备方法 | |
| CN103721191A (zh) | 一种治疗妇女慢性盆腔炎的中药灌肠剂及其制备方法 | |
| CN105031135A (zh) | 一种治疗肝肾虚损型痛经的中药组合物及其制备方法 | |
| CN105267895A (zh) | 用于治疗牛产后血瘀型胞衣不下的药物及其制备方法 | |
| CN105056073A (zh) | 医治心律失常的中药制剂及制备方法 | |
| CN104338086A (zh) | 一种治疗慢性子宫内膜炎的中药灌肠剂及其制备方法 | |
| CN106266548A (zh) | 治疗慢性胃炎的中药组合物、制备方法及其中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150204 |
|
| RJ01 | Rejection of invention patent application after publication |